North of Tyne, Gateshead and North Cumbria
Area Prescribing Committee

Minutes of the meeting held on Tuesday 9th October 2018 Walkergate Park Hospital

Present:

Pat Bottrill	Lay Representative	
David Campbell (Chair)	Chief Pharmacist/Clinical Director for Medicines Optimisation	NHCT
Ian Campbell	Assistant Director, Pharmacy and Medicines Optimisation	NUTH
Sarah Chandler	Formulary Pharmacist	NHCT
Tim Donaldson	Chief Pharmacist/Controlled Drugs Accountable Officer	NTW
Paul Fieldhouse	Clinical Director of Pharmacy Services	NCUHT
Neil Gammack	Chief Pharmacist	GHFT
Tomal Karim		ST&G LPC
Steve Llewellyn	Medicines Optimisation Pharmacist	NGCCG
Matthew Lowery	Formulary and Audit Pharmacist	NUTH
Helen Seymour	Senior Pharmacist	NECS
Sheetal Sundeep	Consultant Microbiologist	NHCT
Graham Syers	Prescribing Lead	N CCG
Susan Turner	Pharmacist	NECS
Hannah Willoughby	Pharmacist	NGCCG

Apologies

Sue Dickinson	Director of Pharmacy	RDTC
Ruth Evans	Medical Director	NT CCG
Matt Grove	Consultant Rheumatologist and Head of Service	NHCT
Andrea Loudon	Primary Care Development and Medicines Lead	NC CCG
Frank McAulay	Associate Medical Director	GHFT
Neil Morris	Medical Director	NG CCG
Neil Watson	Clinical Director of Pharmacy and Medicines Optimisation	NUTH

GHFT	Gateshead Health NHS Foundation Trust
NG CCG	Newcastle Gateshead CCG
NT CCG	North Tyneside CCG
NC CCG	North Cumbria CCG
NCUHT	North Cumbria University Hospitals Trust
NCCG	Northumberland CCG
NoT LPC	North of Tyne Local Pharmaceutical Committee
NHSE	NHS England
NHCT	Northumbria Healthcare NHS Foundation Trust
NECS	North of England Commissioning Support Organisation
NTWT	Northumberland Tyne and Wear NHS Foundation Trust
NUTH	Newcastle upon Tyne Hospitals NHS Foundation Trust
RDTC	Regional Drugs and Therapeutics Centre
ST&G LPC	South Tyneside and Gateshead LPC

Tomal Karim indicated that a new LPC representative will replace him on the committee from January

2018/55	**Declarations of interest** Annual declarations due.
2018/56	**Appeals against previous decisions** No appeals were presented. Notification has been received of the intent to appeal the decision taken in July relating to desmopressin 25 microgram & 50 microgram oral lyophilisate (Noqdirna®) for the treatment of nocturia due to idiopathic nocturnal polyuria in adults. This appeal will be heard in January.
2018/57	**Minutes and decision summary from previous meeting.** The following documents were accepted as a true record: • Decision summary from 10 /7/18. • Minutes from 10 /7/18.
2018/58	**Matters arising not on the agenda or Action Log.** None.
2018/59	**Action Log** The action log was reviewed and will be updated to reflect the following: • 2017/41 The previous request for povidone-iodine sterile aqueous solution was approved subject to an evaluation, with defined end points guided by WHO guidance, being returned to FSC in 6 months. Northumbria clinicians have agreed to undertake this audit. To be progressed with an extension to completion of Jan 2019. • 2017/51 Sufentanil 15microgram sublingual tablets (Zalviso®). An initial evaluation, after use in 70 patients, was received by the FSC. As the evaluation has not highlighted any issues the Formulary Subcommittee have recommended that sufentanil remains on formulary (Red status) to allow Gateshead to carry on using it up to 100 patients, after which another evaluation report on patient outcomes, duration of stay and the impact on nursing time will be required. • 2018/27 Corticosteroid foam enemas – captured under MGUG business. Remove from action log. • 2018/28 Items which should not be routinely prescribed in primary care: Liothyronine guidance for CCGs. Leaflet presented under MGUG business – remove from action log. • 2018/48 Branded Prescribing document . Presented under MGUG agenda item including a statement to reflect an understanding of the issues around branded generic prescribing. Remove from action log. • 2018/54 Opioids and pain management . Task and finish group, including Public Health England, to co-ordinate varying strands of work in relation to medication use in chronic pain set up and due to meet in October. Remove from action log.
2018/60	**Report from the Formulary Sub-committee** The formulary website is available at North of Tyne, Gateshead and North Cumbria Area Prescribing Committee Formulary. **Minutes and recommendations from the North of Tyne, Gateshead and North Cumbria FSC meeting held on 13/9/18:** The above minutes and recommendations were received by the committee. The summary of recommendations made in relation to new product requests is listed in the decision summary.

	The following specific points were highlighted: **Sufentanil** An evaluation report was received from QE Gateshead regarding use of sufentanil for total knee replacement in 70 patients. Main findings: • Equivalent pain relief (68% of patients felt pain was reduced by 50%). • Side effect profile good. • Length of stay comparable to existing therapies (around 3.2 days). • Reduced nursing time for making up and administering drugs • Facilitated the patients' mobility. • Time patients had to wait to receive pain relief reduced. • 27% of patients would not use the device again as they felt it was not appropriate for the pain. The product does not appear to offer any additional benefits compared to other agents in terms of pain relief, with the main benefits being a reduction in nursing time. It was noted that Northumbria and Newcastle trusts do not intend to use the device at this time. As the evaluation has not highlighted any issues the Formulary Subcommittee have recommended that sufentanil remains on formulary (Red status) to allow Gateshead to carry on using it up to 100 patients, after which another evaluation report will be required. **Oxycodone** It was noted that oxycodone is being used as a first line agent in fast track surgery in some centres and that a formulary application is required to support this. **Valproate** Pregnancy prevention link to be added to the formulary. Links to the formulary entries for other drugs with pregnancy prevention programmes will also be added. **MHRA Ulipristal advice** Recent Ulipristal MHRA advice has resulted in a question about whether this should now be removed from the formulary. ML to discuss further with specialists at Northumbria and feed back to the committee.

2018/61	**Process for Devices / wound management /catheter review** The committee was made aware that there are currently separate reviews under way for catheter products used and/or initiated in the Northumbria and Newcastle areas. The remit of the committee includes all prescribable products including related pharmaceutical products that are used like medicines but are classified as medical devices, borderline substances and prescribable nutritional supplements. These reviews are not currently part of the formulary subcommittee processes and therefore the best process to ensure cost effective use of a limited formulary of products, applicable across the whole of the APC area, was discussed. Current data shows that there are increasing overall costs and cost/capita for continence products as well as wide variance across the area in terms of cost/capita and products used. The APC agreed that there should be one formulary across the whole of its area, that it should act as a facilitator in the process of achieving that and that strong leadership of review groups was required. A task and finish group to agree a catheter formulary, with a clear mandate to control costs and rationalise choices, will be set up under the remit of the APC. However, it was acknowledged that further information was needed to understand the reasons for variance in expenditure to inform decisions about membership of the group. It was also agreed that an understanding of the approaches in the best performing parts of the region could help inform the process needed.
2018/62	**Report from the Medicines Guidelines and Use Group** Draft minutes from the meeting held on 3/9/18 were received and noted. Discussions are underway relating to the problems parents, the service and GPs often have prescribing and dispensing specialist specials. There are cost and safety issues to be explored but the desire is to streamline processes to make them easier for all involved. There are different processes in place across the region for managing shared care requests and the RMOC is involved in trying to shape guidance in this area. DC asked for clarity about the future of the North Cumbria APC and whether guidelines produced at MGUG apply in North Cumbria. PF informed the committee that the North Cumbria APC is still meeting but that there are ongoing discussions as to the most appropriate way of working to ensure engagement and consistency across the region. TD highlighted the added complication of the wider geography covered by the Cumbria partnership trust. Guidelines/Information sheets for approval • Newcastle, North Tyneside, Northumberland and Gateshead Guidelines for the Monitoring of Immune Modifying Drugs (IMDs) in Stable Adult Patients (excluding post transplantation) in Primary and Secondary Care – update – approved. • Antipsychotic Drugs – Prescribing & Monitoring in Adults Information for Primary Care – update – concern raised by Gateshead representatives about the removal of the statement clarifying that there is exclusion for

	low-dose antipsychotics for BPSD. The leaflet was approved subject to clarification with the authors that it was appropriate to reinstate this statement. TD to clarify and forward amended leaflet to ST for publication and distribution. • Denosumab information leaflet – update – approved. • Blood-glucose-monitoring-guideline – update – approved. • Brand name prescribing – update – approved. • Liothyronine – information sheet – approved. • Corticosteroid foam enemas – patient letter – approved.
2018/63	**RMOC** The following RMOC recommendations were received : • July RMOC briefing paper on adalimumab https://www.sps.nhs.uk/articles/rmoc-briefing-on-adalimumab-no-3 • Adalimumab toolkit for commissioners and providers https://www.sps.nhs.uk/articles/adalimumab-toolkit-for-commissioners-and-providers • NHSE Contractual commissioning intentions – Adalimumab The APC received and noted these recommendations.
2018/64	**SPS** The following SPS publication was received • Free of charge (FOC)medicines schemes The APC noted the recommendations and encouraged all members to ensure that systems in place were compliant with the guidance.
2018/65	**Northern (NHS) Treatment Advisory Group (N-TAG)** The following recommendations were finalised by NTAG at their meeting on the 4th September 2018 and are now available on the website: • Ferric Maltol for the treatment of iron-deficiency anaemia in Inflammatory Bowel Disease only (updated) • Ferric Maltol for the treatment of iron-deficiency anaemia in patients without Inflammatory Bowel Disease • Lycra Garments for the management of cerebral palsy and other neurological or musculoskeletal conditions (reviewed) The formulary will reflect these recommendations.
2018/66	**NICE Technology Appraisals** The formulary will be amended to reflect the following: • TA TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis • TA528 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer • TA529 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer • TA530 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy • TA531 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer • TA532 Cenegermin for treating neurotrophic keratitis • TA533 Ocrelizumab for treating relapsing–remitting multiple sclerosis • TA534 Dupilumab for treating moderate to severe atopic dermatitis • TA535 Lenvatinib and sorafenib for treating differentiated thyroid cancer

	after radioactive iodine • TA536 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer • TA537 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs • TA538 Dinutuximab beta for treating neuroblastoma • TA539 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours • TA540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma • TA541 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
2018/67	**NHS England** The following NHS England communications were noted and will be reflected in the formulary: • SSC1881 - Addition of Glycerol Phenylbutyrate (Ravicti) to the list of drugs commissioned by NHS England • SSC1883 - NICE Technology Appraisal Final Appraisal Determination: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer • SSC1884 - NICE Technology Appraisal 516: Cabozantinib for treating medullary thyroid cancer • SSC1885 - NICE Technology Appraisal 513: Obinutuzumab for untreated advanced follicular lymphoma • SSC1886 - NICE Technology Appraisal 512: Tivozanib for treating advanced renal cell carcinoma • SSC1889 - NICE Final Appraisal Determination: ROS-1 testing for crizotinib for treating ROS1-positive advanced non-small-cell lung cancer • SSC1890 - NICE Technology Appraisal Final Appraisal Determination: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine • SSC1893 - Publication of New Clinical Policies and Service Specifications Following Prioritisation and Consideration of In Year Service Developments • SSC1894 - NICE Technology Appraisal 518: Tocilizumab for treating giant cell arteritis • SSC1895 - NHS Framework Agreements for the Supply of Icatibant and C1-Esterase Inhibitor (CM/PHS/15/5500) and products for the treatment of bleeding disorders(CM/PHS/15/5499) • SSC1896 - NICE Technology Appraisal Final Appraisal Determination: dinutuximab beta for treating high-risk neuroblastoma • SSC1897 - Use of atezolizumab or pembrolizumab as 1st line treatment of locally advanced/metastatic urothelial cancer in patients ineligible for cisplatin-based chemotherapy • SSC1898 - NICE TA 525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy • SSC1899 - NICE TA 517: Avelumab for treating metastatic Merkel cell carcinoma • SSC1901 - NICE TA FAD: lutetium (177Lu) oxodotreotide for treating

	unresectable or metastatic neuroendocrine tumours • SSC1902 - NICE TA FAD: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma • SSC1904 - EAMS: Patisiran-LNP for the treatment of adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) • SSC1905 - NICE TA FAD: inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia • SSC1906 - Normal Human Immunoglobulin availability and supply • SSC1911 - NICE TA 520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy • SSC1913 - NICE TA FAD: inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia • SSC1914 - Clinical Commissioning Policy: Anakinra to treat periodic fevers and auto-inflammatory diseases (all ages) NHS England Reference: 170062P (follow up to SSC1893: Bi-Annual Prioritisation) • SSC1916 - Clinical Commissioning Policy: Bortezomib for Relapsed/ Refractory Waldenstrom's Macroglobulinaemia • SSC1917 - NICE TA 536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer • SSC1921 - NICE TA 523: Midostaurin for untreated acute myeloid leukaemia • SSC1922 - NICE TA 524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma • SSC1923 - Review of the evidence for the use of Ibrutinib in previously treated patients with chronic lymphocytic leukaemia • SSC1925 - NICE TA 526: Arsenic trioxide for treating acute promyelocytic leukaemia
2018/68	**Bayer and Novartis v NE CCGs** The committee noted the outcome of the recent court challenge by Bayer Plc ("Bayer") and Novartis Pharmaceuticals UK Ltd ("Novartis") as to the lawfulness of a policy for the treatment of wAMD adopted by twelve Clinical Commissioning Groups in this region.
2018/69	**Chair's action** None
2018/70	**Any other business** None
	Date and time of next meeting(s) Tuesday 8th January 2019 12:30 pm Conference room 2 Walkergate Park Hospital 4 Benfield Rd Newcastle upon Tyne NE6 4QD Tuesday 2nd April 2019 12:30 pm Conference room 2 Walkergate Park Hospital 4 Benfield Rd Newcastle upon Tyne NE6 4QD Tuesday 9th July 2019 12:30 pm Rooms 4 & 5

	Education Centre Wansbeck General Hospital Tuesday 8th October 2019 12:30 pm Conference room 2 Walkergate Park Hospital 4 Benfield Rd Newcastle upon Tyne NE6 4QD
	Signed: **Date:** 16/1/19 (Chair of the APC)

North of Tyne, Gateshead and North Cumbria Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Tuesday 9th October 2018.**

Classification of products:

R = 'RED' drugs for hospital use only
A = 'AMBER' drugs suitable for use under Shared Care arrangements
G+ = 'GREEN PLUS – Drugs normally recommended or initiated by hospital specialist, but where the provision of an information leaflet may be appropriate to facilitate continuing treatment by GPs. Many of these information sheets are in the process of development.
G = 'GREEN' – Drugs where initiation by GPs is appropriate.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
None				
2) New Requests				
Eptifibatide Infusion (Integrilin®)	✓ R			Eptifibatide is a glycoprotein IIb/IIIa inhibitor licensed for use in cardiology in procedures such as PCI. Eptifibatide has been requested by the neurointerventional radiologists for use in acute intravascular thrombosis during neurointerventional procedures (unlicensed indication). This is an alternative to abciximab, which is no longer available. The majority of procedures are for intracranial aneurysms. Case series support the use of rescue therapy Decision: The request for eptifibatide was approved for neurointerventional procedures

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Levonorgestrel 20mcg/24hrs Intrauterine Device (Levosert®)		✓		Levosert® is a similar product to Mirena®. It is currently only licenced for 4 years and it isn't licensed for endometrial protection in women undergoing HRT. It is a larger size than existing formulary choices which may cause some issues with insertion. Over 4 years Levosert® is only marginally cheaper than its competitors and it was felt that this saving would be negated by the requirement for additional training in primary care. It was felt Levosert® would only be cost effective if a 5 year licence is obtained (anticipated next year). Decision: The request for Levosert® was refused. The committee agreed to reconsider the application once the 5 year license is approved.
3) New formulations & extensions to use				
None				
4) NHS England Specialised Services communications noted and endorsed by APC				
SSC1881 - Addition of Glycerol Phenylbutyrate (Ravicti) to the list of drugs commissioned by NHS England				The formulary will reflect the NHS England position
SSC1883 - NICE Technology Appraisal Final Appraisal Determination: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer				The formulary will reflect the NHS England position
SSC1884 - NICE Technology Appraisal 516: Cabozantinib for treating medullary thyroid cancer				The formulary will reflect the NHS England position
SSC1885 - NICE Technology Appraisal 513: Obinutuzumab for untreated advanced follicular lymphoma				The formulary will reflect the NHS England position
SSC1886 - NICE Technology Appraisal 512: Tivozanib for treating advanced renal cell carcinoma				The formulary will reflect the NHS England position
SSC1889 - NICE Final Appraisal Determination: ROS-1 testing for crizotinib for treating ROS1-positive advanced non-small-cell lung cancer				The formulary will reflect the NHS England position
SSC1890 - NICE Technology Appraisal Final Appraisal Determination: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine				The formulary will reflect the NHS England position
SSC1893 - Publication of New Clinical Policies and Service Specifications Following Prioritisation and Consideration of In Year Service Developments				The formulary will reflect the NHS England position

Product	Decision Approved | Refused | Deferred	Comments/notes
SSC1894 - NICE Technology Appraisal 518: Tocilizumab for treating giant cell arteritis		The formulary will reflect the NHS England position
SSC1895 - NHS Framework Agreements for the Supply of Icatibant and C1-Esterase Inhibitor (CM/PHS/15/5500) and products for the treatment of bleeding disorders (CM/PHS/15/5499)		The formulary will reflect the NHS England position
SSC1896 - NICE Technology Appraisal Final Appraisal Determination: dinutuximab beta for treating high-risk neuroblastoma		The formulary will reflect the NHS England position
SSC1897 - Use of atezolizumab or pembrolizumab as 1st line treatment of locally advanced/metastatic urothelial cancer in patients ineligible for cisplatin-based chemotherapy		The formulary will reflect the NHS England position
SSC1898 - NICE TA 525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy		The formulary will reflect the NHS England position
SSC1899 - NICE TA 517: Avelumab for treating metastatic Merkel cell carcinoma		The formulary will reflect the NHS England position
SSC1901 - NICE TA FAD: lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours		The formulary will reflect the NHS England position
SSC1902 - NICE TA FAD: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma		The formulary will reflect the NHS England position
SSC1904 - EAMS: Patisiran-LNP for the treatment of adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)		The formulary will reflect the NHS England position
SSC1905 - NICE TA FAD: inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia		The formulary will reflect the NHS England position
SSC1906 - Normal Human Immunoglobulin availability and supply		The formulary will reflect the NHS England position
SSC1911 - NICE TA 520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy		The formulary will reflect the NHS England position
SSC1913 - NICE TA FAD: inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia		The formulary will reflect the NHS England position
SSC1914 - Clinical Commissioning Policy: Anakinra to treat periodic fevers and auto-inflammatory diseases (all ages) NHS England Reference: 170062P (follow up to SSC1893: Bi-Annual Prioritisation)		The formulary will reflect the NHS England position

Product	Decision Approved | Refused | Deferred	Comments/notes
SSC1916 - Clinical Commissioning Policy: Bortezomib for Relapsed/ Refractory Waldenstrom's Macroglobulinaemia		The formulary will reflect the NHS England position
SSC1917 - NICE TA 536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer		The formulary will reflect the NHS England position
SSC1921 - NICE TA 523: Midostaurin for untreated acute myeloid leukaemia		The formulary will reflect the NHS England position
SSC1922 - NICE TA 524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma		The formulary will reflect the NHS England position
SSC1923 - Review of the evidence for the use of Ibrutinib in previously treated patients with chronic lymphocytic leukaemia		The formulary will reflect the NHS England position
SSC1925 - NICE TA 526: Arsenic trioxide for treating acute promyelocytic leukaemia		The formulary will reflect the NHS England position
5) Products considered by NICE		
TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis		The formulary will reflect the NICE TAG
TA528 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer		The formulary will reflect the NICE TAG
TA529 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer		The formulary will reflect the NICE TAG
TA530 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy		The formulary will reflect the NICE TAG
TA531 Pembrolizumab for untreated PD-L1-positive		The formulary will reflect the NICE TAG
TA532 Cenegermin for treating neurotrophic keratitis		The formulary will reflect the NICE TAG
TA533 Ocrelizumab for treating relapsing–remitting multiple sclerosis		The formulary will reflect the NICE TAG
TA534 Dupilumab for treating moderate to severe atopic dermatitis		The formulary will reflect the NICE TAG
TA535 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine		The formulary will reflect the NICE TAG
TA536 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer		The formulary will reflect the NICE TAG
TA537 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs		The formulary will reflect the NICE TAG
TA538 Dinutuximab beta for treating neuroblastoma		The formulary will reflect the NICE TAG
TA539 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours		The formulary will reflect the NICE TAG

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma				The formulary will reflect the NICE TAG
TA541 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia				The formulary will reflect the NICE TAG
6) Northern (NHS) Treatment Advisory Group (N-TAG)				
Ferric Maltol for the treatment of iron-deficiency anaemia in Inflammatory Bowel Disease only (updated)				The formulary will reflect the NTAG position
Ferric Maltol for the treatment of iron-deficiency anaemia in patients without Inflammatory Bowel Disease				The formulary will reflect the NTAG position
Lycra Garments for the management of cerebral palsy and other neurological or musculoskeletal conditions (reviewed)				The formulary will reflect the NTAG position
7) Appeals against earlier decisions by the APC				
None				
8) Miscellaneous decisions by the APC				
None				